## Effects of adherence to guidelines for the control of maj on outcomes in the REduction of Atherothrombosis for Registry Europe

Heart 97, 660-667 DOI: 10.1136/hrt.2010.213710

**Citation Report** 

#	Article	IF	CITATIONS
1	Improving cardiovascular prevention through patient awareness. Revista Da Associação Médica Brasileira, 2012, 58, 550-556.	0.7	4
2	Global Variation in the Prevalence of Elevated Cholesterol in Outpatients With Established Vascular Disease or 3 Cardiovascular Risk Factors According to National Indices of Economic Development and Health System Performance. Circulation, 2012, 125, 1858-1869.	1.6	39
3	Improving cardiovascular prevention through patient awareness. Revista Da Associação Médica Brasileira, 2012, 58, 550-556.	0.7	3
4	Improving cardiovascular prevention through patient awareness. Revista Da Associação Médica Brasileira (English Edition), 2012, 58, 550-556.	0.1	0
5	The Year in Atherothrombosis. Journal of the American College of Cardiology, 2012, 60, 932-942.	2.8	14
6	Polyvascular Disease in Patients Presenting with Acute Coronary Syndrome: Its Predictors and Outcomes. Scientific World Journal, The, 2012, 2012, 1-7.	2.1	18
7	Disparity in risk factor pattern in premature versus late-onset coronary artery disease: a survey of 15,381 patients. Vascular Health and Risk Management, 2012, 8, 473.	2.3	34
8	Two-year Vascular Hospitalisation Rates and Associated Costs in Patients at Risk of Atherothrombosis in France and Germany: Highest Burden for Peripheral Arterial Disease. European Journal of Vascular and Endovascular Surgery, 2012, 43, 198-207.	1.5	56
9	Optimal medical therapy predicts amputation-free survival in chronic critical limb ischemia. Journal of Vascular Surgery, 2013, 58, 972-980.	1.1	55
10	Relation of serum uric acid and body mass index to mortality in high-risk patients with established coronary artery disease: A report from the ET-CHD registry, 1997–2006. Journal of Cardiology, 2013, 62, 354-360.	1.9	15
11	Almanac 2013: stable coronary artery disease. Wiener Klinische Wochenschrift, 2013, 125, 776-783.	1.9	0
12	Secondary prevention in patients with vascular disease. A population based study on the underuse of recommended medications. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 348-353.	1.9	27
13	Almanac 2013: stable coronary artery disease. Heart, 2013, 99, 1652-1657.	2.9	0
14	Perspectives: The burden of cardiovascular risk factors and coronary heart disease in Europe and worldwide. European Heart Journal Supplements, 2014, 16, A7-A11.	0.1	49
15	Health-related quality of life and risk factor control: the importance of educational level in prevention of cardiovascular diseases. European Journal of Public Health, 2014, 24, 679-684.	0.3	24
16	Effectiveness of antiplatelet therapy in atherosclerotic disease: comparing the ASA low-response prevalence in CVD, CAD and PAD. Journal of Thrombosis and Thrombolysis, 2014, 37, 190-201.	2.1	7
17	Evidence-to-practice gaps in post-stroke management: a focus on care in a stroke unit and anticoagulation to prevent death, disability and recurrent stroke. Future Neurology, 2014, 9, 449-459.	0.5	0
18	As REGARDS Treatment Goal Attainment Compared With COURAGE. Journal of the American College of Cardiology, 2014, 63, 1634-1635.	2.8	1

#	Article	IF	Citations
19	Assessment of potential cardiovascular risks of methylphenidate in comparison with sibutramine: do we need a SCOUT (trial)?. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 233-247.	3.2	11
20	Coronary revascularization induces a shift from cardiac toward noncardiac mortality without improving survival in vascular surgery patients. Journal of Vascular Surgery, 2015, 61, 1543-1549.e1.	1.1	8
21	Guideline-adherent therapy in patients with cardiovascular diseases in Taiwan. Journal of the Formosan Medical Association, 2015, 114, 1000-1007.	1.7	16
22	3-Year Outcomes of the OLIVE Registry, a Prospective Multicenter Study of Patients With Critical Limb Ischemia. JACC: Cardiovascular Interventions, 2016, 9, 201-202.	2.9	Ο
23	Peripheral artery disease patients may benefit more from aggressive secondary prevention than aneurysm patients to improve survival. Atherosclerosis, 2016, 252, 147-152.	0.8	4
24	Impact of cardiovascular risk factor control on long-term cardiovascular and all-cause mortality in the general population. Annals of Medicine, 2016, 48, 559-567.	3.8	10
25	Implementation of a telephone-based secondary preventive intervention after acute coronary syndrome (ACS): participation rate, reasons for non-participation and 1-year survival. Trials, 2016, 17, 85.	1.6	8
26	Underuse of Prevention and LifestyleÂCounseling in Patients With Peripheral Artery Disease. Journal of the American College of Cardiology, 2017, 69, 2293-2300.	2.8	140
27	Temporal trends in the premorbid use of preventive treatments in patients with acute ischemic cerebrovascular events and a history of vascular disease: The Dijon Stroke Registry (1985–2010). Presse Medicale, 2017, 46, e259-e267.	1.9	1
28	Unfavourable risk factor control after coronary events in routine clinical practice. BMC Cardiovascular Disorders, 2017, 17, 40.	1.7	16
29	An intelligent system for prognosis of noncommunicable diseases' risk factors. Telematics and Informatics, 2018, 35, 1222-1236.	5.8	13
30	Primary prevention of stroke and cardiovascular disease in the community (PREVENTS): Methodology of a health wellness coaching intervention to reduce stroke and cardiovascular disease risk, a randomized clinical trial. International Journal of Stroke, 2018, 13, 223-232.	5.9	9
31	The Society for Vascular Surgery practice guidelines on follow-up after vascular surgery arterial procedures. Journal of Vascular Surgery, 2018, 68, 256-284.	1.1	117
32	Unsatisfactory risk factor control and high rate of new cardiovascular events in patients with myocardial infarction and prior coronary artery disease. BMC Cardiovascular Disorders, 2019, 19, 71.	1.7	24
33	Treatment target achievement after myocardial infarction and ischaemic stroke: cardiovascular risk factors, medication use, and lifestyle: the TromsÃ, Study 2015–16. European Journal of Preventive Cardiology, 2022, 29, 362-370.	1.8	6
34	Peripheral artery disease in Germany (2009–2018): Prevalence, frequency of specialized ambulatory care and use of guideline-recommended therapy – A population-based study. Lancet Regional Health - Europe, The, 2021, 5, 100113.	5.6	24
35	The Association of Visceral Adiposity with Cardiovascular Events in Patients with Peripheral Artery Disease. PLoS ONE, 2013, 8, e82350.	2.5	10
36	Therapeutic Potential of Modulating MicroRNA in Peripheral Artery Disease. Current Vascular Pharmacology, 2015, 13, 316-323.	1.7	30

CITATION REPORT

**CITATION REPORT** IF ARTICLE CITATIONS PREVALENCE OF MULTI-FOCAL ATHEROSCLEROTIC PATHOLOGY ACROSS AGE GROUPS. Cardiovascular 37 1.4 0 Therapy and Prevention (Russian Federation), 2013, 12, 63-69. Almanac 2013: stable coronary artery disease. Seminars in Cardiovascular Medicine, 2013, 19, 72-80. Almanac 2013: Stable coronary artery disease the national society journals present selected research 39 0.1 0 that has driven recent advances in clinical cardiology. Srce I Krvni Sudovi, 2014, 33, 288-294. Long-term hospital-based secondary prevention of coronary artery disease: a randomized controlled trial. BMC Cardiovascular Disorders, 2021, 21, 600. Time trends in incidence, treatment, and outcome in acute myocardial infarction in Norway 2013–19. 42 2.3 1 European Heart Journal Open, 2022, 2, . Achievement of the ESC recommendations for secondary prevention of cardiovascular risk factors in high-risk patients with type 2 diabetes: A real-world national cohort analysis. International Journal of Cardiology, 2023, 377, 104-111. 1.7 Adherence to cardiovascular prevention guidelines in an academic center. CJC Open, 2023, , . 44 1.5 0 Outcomes among patients with peripheral artery disease in the Aspirin Dosing: A Patient-Centric Trial 1.5 Assessing Benefits and Long-Term Effectiveness (ADAPTABLE) study. Vascular Medicine, 2023, 28, 122-130. Association of Troponin T measurements with long-term outcomes in patients with coronary artery 46 1.7 0 disease participating in a secondary prevention trial. BMC Cardiovascular Disorders, 2023, 23, . Sex differences in secondary preventive follow-up after coronary heart events. BMC Cardiovascular 1.7 Disorders, 2023, 23, .

#